Australia Makes Birth Control and UTI Care Free to Access

Getting birth control refills or treatment for a urinary tract infection just became easier and cheaper for millions of Australian women.

Starting in February 2027, eligible women can visit participating pharmacies across Australia for UTI treatment or hormonal contraception consultations at no charge. If the pharmacist prescribes medication, it will cost no more than $25 per prescription, the same as subsidized rates under the Pharmaceutical Benefits Scheme.

Health Minister Mark Butler announced the initiative as part of a nationwide effort to improve women's health access. The 12-month trial builds on existing state programs that have operated with varying rules and costs since 2020.

The change eliminates a significant barrier for many women. Currently, pharmacist consultation fees vary widely across Australia, and some women pay substantial out-of-pocket costs just to talk with a healthcare provider before even purchasing their medication.

For birth control specifically, pharmacists can now prescribe the pill, vaginal ring, and depot injections. This means women who've been taking the pill can get refills without interrupting their contraception, reducing the risk of unintended pregnancy.

UTI treatment through pharmacies has already shown promise in early state trials. Evaluations from Queensland, New South Wales, and the Australian Capital Territory found high rates of symptom resolution and positive patient experiences when pharmacists treated uncomplicated bladder infections.

The nationwide approach also standardizes care across the country. Previously, a woman in one state might have had different access and costs than someone in another state for the same service.

The Bright Side

Beyond cost savings, the pharmacy model offers convenience that traditional doctor visits can't always match. Community pharmacies have extended hours and are widely accessible, making it easier for women to get care around work schedules or in areas with fewer doctors.

Early trials of pharmacy contraceptive services reported high patient satisfaction and few safety concerns. Women appreciated the reduced wait times and the ability to handle routine health needs closer to home.

The trial will run for a full year, giving health officials time to evaluate whether this model works well for Australian women on a national scale. If successful, it could become a permanent feature of women's healthcare access.

For the estimated millions of Australian women who experience UTIs or take hormonal contraception, February 2027 marks the start of simpler, more affordable access to essential care.